Exenatide and sitagliptin are not associated with increased risk of acute renal failure: A retrospective claims analysis

Diabetes, Obesity and Metabolism

Volumn 14, Issue 7, 2012, Pages 596-600

  Pendergrass, M ^a,b   Fenton, C ^c   Haffner, S M ^d   Chen, W ^a  

^a Medco Health Solutions   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Medco Health Solutions ^*

Author keywords

Acute renal failure; DPP 4 inhibitors; Exenatide; GLP 1 agonists; Sitagliptin

Indexed keywords

EXENDIN 4; SITAGLIPTIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 84862777558     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01567.x     Document Type: Article

References (11)

1. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010; 33: 428-433.
2. Weise WJ, Sivanandy MS, Block CA, Comi RJ. Exenatide-associated ischemic renal failure. Diabetes Care 2009; 32: e22-e23.
3. Accessed 5 June 2010.
4. Herman GA, Stevens C, Van Dyck K et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78: 675-688.
5. Kao DP, Kohrt HE, Kugler J. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med 2008; 25: 1229-1230.
6. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45: 197-203.
7. Matveyenko AV, Dry S, Cox HI et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009; 58: 1604-1615.
8. Nachnani JS, Bulchandani DG, Nookala A et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010; 53: 153-159.
9. Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
10. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33: 2349-2354.
11. Waikar SS, Wald R, Chertow GM et al. Validity of International Classification of Diseases, ninth revision, clinical modification codes for acute renal failure. J Am Soc Nephrol 2006; 17: 1688-1694.